Radiomics of MRI for the Prediction of the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Single Referral Centre Analysis
Authors:
- Filippo PesapaneFilippo Pesapane
- Anna RotiliAnna Rotili
- Francesca BottaFBFrancesca Botta
- Sara RaimondiSRSara Raimondi
- Linda BianchiniLBLinda Bianchini
- Federica CorsoFCFederica Corso
- Federica FerrariFFFederica Ferrari
- Silvia PencoSPSilvia Penco
- Luca NicosiaLuca Nicosia
- Anna BozziniABAnna Bozzini
- Maria PizzamiglioMPMaria Pizzamiglio
- Daniela OriggiDODaniela Origgi
Open Access
Abstract
Objectives: We aimed to determine whether radiomic features extracted from a highly homogeneous database of breast MRI could non-invasively predict pathological complete responses (pCR) to neoadjuvant chemotherapy (NACT) in patients with breast cancer. Methods: One hundred patients with breast cancer receiving NACT in a single center (01/2017–06/2019) and undergoing breast MRI were retrospectively evaluated. For each patient, radiomic features were extracted within the biopsy-proven tumor on T1-weighted (T1-w) contrast-enhanced MRI performed before NACT. The pCR to NACT was determined based on the final surgical specimen. The association of clinical/biological and radiomic features with response to NACT was evaluated by univariate and multivariable analysis by using random forest and logistic regression. The performances of all models were assessed using the areas under the receiver operating characteristic curves (AUC) with 95% confidence intervals (CI). Results: Eighty-three patients (mean (SD) age, 47.26 (8.6) years) were included. Patients with HER2+, basal-like molecular subtypes and Ki67 ≥ 20% presented a pCR to NACT more frequently; the clinical/biological model’s AUC (95% CI) was 0.81 (0.71–0.90). Using 136 representative radiomics features selected through cluster analysis from the 1037 extracted features, a radiomic score was calculated to predict the response to NACT, with AUC (95% CI): 0.64 (0.51–0.75). After combining the clinical/biological and radiomics models, the AUC (95% CI) was 0.83 (0.73–0.92). Conclusions: MRI-based radiomic features slightly improved the pre-treatment prediction of pCR to NACT, in addiction to biological characteristics. If confirmed on larger cohorts, it could be helpful to identify such patients, to avoid unnecessary treatment.Keywords
This publication has 39 references indexed in Scilit:
- Magnetic resonance imaging texture analysis classification of primary breast cancerEuropean Radiology, 2015
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Dynamic contrast‐enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancerNMR in Biomedicine, 2014
- Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?Insights into Imaging, 2012
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Ki67 in breast cancer: prognostic and predictive potentialThe Lancet Oncology, 2010
- Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version)Breast Cancer, 2007
- User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliabilityNeuroImage, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survivalThe Breast, 2003